Composition : Alectinib
Strength availability : 150mg
Form : capsules
Pack : 240 capsules
for MORE INFORMATION !!!
Alecensa 150mg belongs to class of second generation oral drug which specificallyprevents the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase.
Alecensa is a prescription drug which used under the guidance of doctor.
It is part used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells.
Alecensa 150mg is used for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
Non- Small Cell Lung Cancer
The usual dose is 600mg PO BID until disease progression or unacceptable
Renal impairment patients dose is 450mg orally twice daily
Alecensa is administrated with food.
Particularly, crizotinibprevents anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, Alectinib is a type of tyrosine kinase inhibitor which target ALK and RET. In nonclinical studies, Alectinib inhibits ALK phosphorylation and ALK-mediated activation of the downstream indicating proteins STAT3 and AKT anddecreases tumor cell viability in multiple cell lines harbouring ALK fusions, elaborations, or activating mutations.
Peak plasma concentration 4 hours and bioavailability of Alecensa 37%
Alectinib bound to human plasma proteins 99%
Metabolized by CYP3A4 to its major active metabolite M4, the main circulating moieties in plasma, total radioactivity 76% constituting.
In oral administration, radioactivity 98% was excreted in feces. 84% dose was excreted in the feces unchanged Alectinib.
Half-life is 33 hours
depends on data from animal studies and its pharmacological action, Alecensa can cause fetal harm when administered to pregnant women.
While Alecensa administration, Symptomatic bradycardia may have observed; control heart rate and blood pressure regularly
Alecensa may causes Severe myalgia and elevated CPK resulted; advise patients to report any unexplained muscle pain, tenderness, or weakness;
Renal impairment occurred during Alecensa treatment; incidence of Grade ≥3 renal impairment was 1.7%, of which 0.5% were fatal events.
No pharmacokinetic interactions with Alecensa 150mg needed dosage adjustment have been observed.
If the patient vomits after taking a dose of ALECENSA or missed to take a dose, then should not to take an extra dose, but to take the next dose at the regular time, skip the missed dose.
Store at below 30℃
Store the drug in original container
Alecensa causes some side effects while administrating certain condition as follows :
COMMON SIDE EFFECTS
Muscle pain, Bradycardia, Tiredness, Constipation, Anemia , Hepatotoxicity, Feeling tired, Feeling less hungry than usual, Dark urine, Itchy skin, Nausea or vomiting, Abdominal Pain on the right side , Bleeding or bruising more easily than normal, Lung Problems, Trouble breathing, Shortness of breath , Cough, Fever .